$80,000 of ASTRAZENECA PHARMACEUTICALS LP lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.946 - ORPHAN Cures Act. Issues related to insurance coverage of specialty treatments."
You can find more data on corporate lobbying on Quiver Quantitative.
AZN Congressional Stock Trading
Members of Congress have traded $AZN stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AZN stock by members of Congress over the last 6 months:
- REPRESENTATIVE BRUCE WESTERMAN purchased up to $15,000 on 03/03.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
AZN Hedge Fund Activity
We have seen 542 institutional investors add shares of AZN stock to their portfolio, and 570 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 15,722,197 shares (+189.3%) to their portfolio in Q4 2024, for an estimated $1,030,118,347
- CAPITAL WORLD INVESTORS removed 6,111,652 shares (-97.7%) from their portfolio in Q4 2024, for an estimated $400,435,439
- MORGAN STANLEY added 4,476,178 shares (+34.9%) to their portfolio in Q4 2024, for an estimated $293,279,182
- HOLOCENE ADVISORS, LP added 4,300,401 shares (+inf%) to their portfolio in Q4 2024, for an estimated $281,762,273
- MARSHALL WACE, LLP added 3,876,961 shares (+inf%) to their portfolio in Q4 2024, for an estimated $254,018,484
- CITADEL ADVISORS LLC added 3,774,365 shares (+841.6%) to their portfolio in Q4 2024, for an estimated $247,296,394
- BOSTON PARTNERS added 3,670,719 shares (+9985.6%) to their portfolio in Q4 2024, for an estimated $240,505,508
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
AZN Analyst Ratings
Wall Street analysts have issued reports on $AZN in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 11/13/2024
To track analyst ratings and price targets for AZN, check out Quiver Quantitative's $AZN forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
